Cannabinoid Biosciences, Inc

Cannabinoid Biosciences, Inc.(“CBDZ”) is a biopharmaceutical company, which intends to engage in the discovery, development and commercialization of cures and novel therapeutics from proprietary cannabinoid, cannabidiol, endocannabinoids, phytocannabinoids, and synthetic cannabinoids product platform suitable for specific treatments in a broad range of disease areas. Our business is divided into four segments namely: 1. Biopharmaceutical Research and Development; 2. Investments into legal-cannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada; 3. Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses; and 4. Professional services including top-level financial reporting, Accounting Two of our business units are in flux and have investment opportunities that we want to capitalize upon immediately: • Rollup and Consolidation: Investments into legal-cannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada; and • Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses. CBDZ is raising $125 million with Reg A+($50 million) and Reg. D 506 (c)($75 million). The Company had filed the required filings with the SEC and is waiting for their go-ahead for the Reg. A+. CBDZ has agreed to rollup 10 dispensaries with $54 million in annual revenue. These rollup will IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE) via Reg. A+, which is already filed with the SEC. Once our Reg A+ is qualified, CBDZ will be listed on the NASDAQ or NYSE. A invested at this ground floor could fetch up to $21,500 based on what the NASDAQ and NYSE market-participants sale-to-market cap multiples for rollup/consolidated Cannabis business.